Bio-Path Holdings announces a new obesity therapeutic program and enrollment completion for a refractory leukemia trial.

Bio-Path Holdings Inc. saw a significant stock price increase following its announcement of a new therapeutic program for BP1001-A, aimed at treating obesity and metabolic diseases, marking its first non-cancer application of DNAbilize technology. Preclinical studies are expected to begin in Q4 2024. Additionally, the company completed enrollment for the third dosing cohort in a trial for BP1002, targeting refractory acute myeloid leukemia patients, including those resistant to venetoclax.

October 08, 2024
4 Articles

Further Reading